Generic name:antihemophilic factor (RECOMBINANT) PEGYLATED-AUCL (intravenous route) [ an-tye-hee-moe-FIL-ik-FAK-tor-ree-KOM-bin-ant-PEG-il-ay-ted-- aucl ]
Drug class:Miscellaneous coagulation modifiers
Medically reviewed by Drugs.com. Last updated on Feb 1, 2022.
Commonly used brand name(s)
In the U.S.
- Jivi
Available Dosage Forms:
- Powder for Solution
Therapeutic Class: Antihemophilic Agent
Uses for Jivi
Antihemophilic factor (recombinant) pegylated-aucl injection is used to treat and control bleeding in patients with hemophilia A (congenital Factor VIII deficiency) who have been treated before. It is also used to reduce the number of bleeding episodes in patients when used regularly. Antihemophilic factor (recombinant) pegylated-aucl injection is also used to prevent bleeding during a surgical procedure.
This medicine is available only with your doctor's prescription.
Before using Jivi
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of antihemophilic factor (recombinant) pegylated-aucl injection in children younger than 12 years of age. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of antihemophilic factor (recombinant) pegylated-aucl injection in the elderly. However, ...
